Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations

INTERVENTION: Trade Name: ERDOTIN Pharmaceutical Form: Capsule, hard INN or Proposed INN: Erdosteine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300‐ CONDITION: COPD exacerbation ; MedDRA version: 9.1 Level: SOC Classification code 10038738 PRIMARY OUTCOME: Main Objective: evaluation of erdosteine activity on systemic inflammation during COPD exacerbation Primary end point(s): erdosteine activity on serum biomarkers of inflammation Secondary Objective: evaluation of erdosteine activity on inflammation biomarkers INCLUSION CRITERIA: hospitalized patiens with COPD exacerbation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range